These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33649485)

  • 41. [Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre-diabetic patients:long-term follow-up of Da Qing Diabetes Prevention Study].
    Chen Y; Wang J; An Y; Gong Q; He Y; Zhang B; Li H; Shuai Y; Tang X; Jiang Y; Hong J; Yang W; Hu Y; Li G
    Zhonghua Nei Ke Za Zhi; 2015 Jan; 54(1):13-7. PubMed ID: 25877139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction: role of type 2 diabetes mellitus.
    Han Z; Yan-min Y; Jun Z; Li-sheng L; Hui-qiong T; Yao L
    BMC Cardiovasc Disord; 2012 Nov; 12():104. PubMed ID: 23153317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential Health Care Use, Diabetes-Related Complications, and Mortality Among Five Unique Classes of Patients With Type 2 Diabetes in Singapore: A Latent Class Analysis of 71,125 Patients.
    Seng JJB; Kwan YH; Lee VSY; Tan CS; Zainudin SB; Thumboo J; Low LL
    Diabetes Care; 2020 May; 43(5):1048-1056. PubMed ID: 32188774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediabetes versus type 2 diabetes mellitus based on pre-percutaneous coronary intervention thrombolysis in myocardial infarction flow grade in patients with ST-segment elevation myocardial infarction after successful newer-generation drug-eluting stent implantation.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Diab Vasc Dis Res; 2021; 18(1):1479164121991505. PubMed ID: 33535819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.
    Laxy M; Schöning VM; Kurz C; Holle R; Peters A; Meisinger C; Rathmann W; Mühlenbruch K; Kähm K
    Pharmacoeconomics; 2019 Dec; 37(12):1485-1494. PubMed ID: 31350720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular event costs in patients with Type 2 diabetes mellitus.
    Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I
    J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
    Malachias MVB; Jhund PS; Claggett BL; Wijkman MO; Bentley-Lewis R; Chaturvedi N; Desai AS; Haffner SM; Parving HH; Prescott MF; Solomon SD; De Zeeuw D; McMurray JJV; Pfeffer MA
    J Am Heart Assoc; 2020 Oct; 9(19):e017462. PubMed ID: 32964800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
    Toulis KA; Willis BH; Marshall T; Kumarendran B; Gokhale K; Ghosh S; Thomas GN; Cheng KK; Narendran P; Hanif W; Nirantharakumar K
    J Clin Endocrinol Metab; 2017 May; 102(5):1719-1725. PubMed ID: 28323967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction.
    van Bergen PF; Deckers JW; Jonker JJ; van Domburg RT; Azar AJ; Hofman A
    Br Heart J; 1995 Aug; 74(2):117-21. PubMed ID: 7546987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study.
    Lin WH; Yang CY; Kuo S; Kuo TH; Roan JN; Li CY; Wang MC; Ou HT
    Diabetes Res Clin Pract; 2021 Feb; 172():108489. PubMed ID: 33035600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
    Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study.
    Martin S; Schneider B; Heinemann L; Lodwig V; Kurth HJ; Kolb H; Scherbaum WA
    Diabetologia; 2006 Feb; 49(2):271-8. PubMed ID: 16362814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
    Ó Hartaigh B; Szymonifka J; Okin PM
    J Hypertens; 2018 Jan; 36(1):101-109. PubMed ID: 28832365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
    Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
    Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
    Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.